CA
ZNTL icon

Carson Advisory’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Carson Advisory’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$103K Sell
21,170
-2,100
-9% -$8.38K 0.05% 203
2026
Q1 		$54.5K Sell
23,270
-200
-0.9% -$517 0.03% 188
2025
Q4 		$31.7K Sell
23,470
-8,600
-27% -$12.5K 0.02% 183
2025
Q3 		$48.4K Buy
32,070
+2,500
+8% +$3.75K 0.03% 173
2025
Q2 		$34.3K Hold
29,570
– – 0.02% 171
2025
Q1 		$47K Buy
29,570
+4,900
+20% +$10.6K 0.03% 164
2024
Q4 		$74.8K Buy
24,670
+100
+0.4% +$328 0.05% 157
2024
Q3 		$90.4K Buy
24,570
+8,800
+56% +$32K 0.06% 177
2024
Q2 		$64.5K Buy
15,770
+3,000
+23% +$33.5K 0.05% 166
2024
Q1 		$201K Buy
+12,770
New +$176K 0.14% 164

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Carson Advisory's ZNTL Position: Q2 2026 in Review

Carson Advisory reduced its Zentalis Pharmaceuticals (ZNTL) stake by 9% in Q2 2026, selling an estimated $8.38K and leaving 21,170 shares worth $103K. The position accounts for 0.05% of the portfolio, ranked #203.

Carson Advisory first reported a position in ZNTL in Q1 2024 and has held it in 10 quarters since. The position peaked at $201K in Q1 2024. 114 funds tracked by Wall St. Rank hold ZNTL as of Q2 2026.

  • Carson Advisory held 21,170 shares of Zentalis Pharmaceuticals worth $103K as of Q2 2026.
  • Carson Advisory sold 2,100 Zentalis Pharmaceuticals shares in Q2 2026, an estimated $8.38K.
  • Zentalis Pharmaceuticals made up 0.05% of Carson Advisory's portfolio in Q2 2026, its #203 holding.
  • Carson Advisory first reported a position in Zentalis Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
  • Carson Advisory's Zentalis Pharmaceuticals position peaked at $201K in Q1 2024.
  • 114 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2026.

Based on Carson Advisory's 13F filing for Q2 2026, filed 11 Aug 2026.